Article Text

PDF
CASE REPORT
Olmesartan-induced enteropathy
  1. Nirmal K Onteddu1,
  2. Venkata Siva Krishna Kumar Pulivarthi2,
  3. Mihira Ginnavaram3,
  4. Ramalinga Kedika4
  1. 1Internal Medicine, Texas Tech University Health Sciences Center at Permian Basin, Odessa, Texas, USA
  2. 2Department of CT Surgery, Mayo Clinic Research Arizona, Scottsdale, Arizona, USA
  3. 3Internal Medicine, Bhaskar Medical College, Ranga Reddy, Telangana, India
  4. 4Gastroenterology, ProCare Gastroenterology, Odessa, Texas, USA
  1. Correspondence to Dr Nirmal K Onteddu, nkumarreddyo{at}gmail.com, nkumarreddyo{at}gmail.com

Summary

Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. We describe a 68-year-old Caucasian woman with a history of hypothyroidism and hypertension who presented to our hospital with recurrent episodes of acute intermittent diarrhoea, nausea, vomiting, renal failure and 15 lbs weight loss. After an extensive workup, she was diagnosed with possible OIE. Cessation of the offending drug resulted in improvement of clinical symptoms and also hospital admissions for severe diarrhoea reinforcing the diagnosis of OIE. Among the adverse effects of drug therapy, diarrhoea is a relatively frequent adverse event accounting for about 7%. This report serves as an addition to existing literature and to increase the awareness of olmesartan-induced sprue-like enteropathy among the primary care physicians and gastroenterologists.

  • endoscopy
  • coeliac disease
  • unwanted effects / adverse reactions
  • hypertension

Statistics from Altmetric.com

Footnotes

  • Contributors All authors contributed to the revision and approval of the manuscript. NKO, VSKKP and MG drafted the manuscript. NKO, VSKKP and RK collected data, revision of manuscript and edited the images. NKO is the article guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.